Trump Reports $1.4 Billion in Crypto Income as Digital Assets Become Top Wealth Source 
Trump Dedicates Theodore Roosevelt Museum, Unveils New Air Force One Ahead of America’s 250th Anniversary 
Trump Suspends Some Morocco Fertilizer Tariffs to Ease U.S. Supply Shortage 
US-Iran Doha Talks Show Limited Progress as Hormuz Shipping Remains Key Focus 
Trump Administration Declines USMCA Renewal, Opens Talks on New Trade Changes 
UN Chief Urges Nations to Close $100 Million UNRWA Funding Gap 
India Manufacturing PMI Slows in June as Demand Weakens Despite Lower Cost Pressures 
South Korea Warns Won Is Undervalued, Boosts FX Coordination With Japan 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Ukraine War: Russian Drone Attack Sparks Hotel Fire in Central Kyiv 
RBA Minutes Signal Australia Central Bank Remains Ready to Raise Interest Rates if Inflation Persists 
Asian Currencies Slip as Dollar Holds Firm, Yen Near Four-Decade Low Ahead of Fed, Jobs Data 
Wall Street Futures Rise Ahead of JOLTS Data, Nike Earnings, and U.S.-Iran Talks 
Central Banks Eye Gold, Reduce Dollar Exposure as AI Adoption Accelerates: OMFIF Survey 
Greece’s Bad Loan Crisis Continues to Limit Credit Access Despite Economic Recovery 
Gold Price Hits Annual Low as Fed Rate Hike Bets and Sticky Inflation Weigh on Bullion 
Asian Stocks End Strong Quarter as Dollar Surges, Yen Hits 40-Year Low Ahead of US Jobs Data 
US healthcare stocks have fallen sharply following President-elect Donald Trump's cabinet picks. The nomination of Robert F. Kennedy Jr. as Secretary of Health and Human Services has alarmed investors due to his critical stance on vaccines and obesity drugs, sparking fears of significant regulatory shifts.
Trump's Election Spurs Healthcare Stock Decline in US and Europe
Barclays reports that since Donald Trump's election on November 5, healthcare stocks in the US and Europe have fallen due to growing concerns about the possible policy effects of his cabinet nominees, Investing.com shares.
The healthcare industry as a whole has lagged larger indexes; for example, the U.S. healthcare ETF is down nearly 7% from the S&P 500, and healthcare equities in Europe are down roughly 1.5% from the broader European index.
There have been strong protests to Robert F. Kennedy Jr.'s nomination to head HHS, particularly in the pharmaceutical and biotech industries.
Kennedy's Controversial Stance on Vaccines and Obesity Drugs
Possible regulatory roadblocks have been heightened by Kennedy's reputation for vaccination skepticism and criticism of obesity medications.
Concerns have been raised by Kennedy's remarks on the FDA's policy, vaccines, and GLP-1 medications for obesity.
It may be difficult to turn these ideas into practical policy, according to analysts at Barclays.
Medicare only pays for GLP-1 medications, such as Novo Nordisk semaglutide, for obese individuals who meet the SELECT trial's criteria for shown cardiovascular risk. Modifications to the Treat and Reduce Obesity Act (TROA) would be necessary to expand coverage.
Barclays Sees Opportunity Despite Investor Skepticism
The commercial market, not Medicaid or Medicare, is the main driver of growth for anti-obesity pharmaceuticals, according to Barclays.
Regarding vaccination policies, investors are even more skeptical due to Kennedy's anti-vaccine stance.
As a result of Kennedy's nomination, Novo Nordisk and Sanofi stocks have been "unduly punished," according to Barclays. Barclays sees the selloff as an overreaction and has maintained "overweight" ratings for both firms.
While healthcare is still facing some short-term problems, Barclays does point out that certain subsectors might eventually profit from more defined rules.
Broader Cabinet Picks Add to Market Uncertainty
Even more so than with Kennedy's nomination, investors are worried about regulatory uncertainty due to Trump's wider cabinet nominations, such as Vivek Ramaswamy to the Department of Government Efficiency.
